1/6
08:35 am
otlk
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
Low
Report
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
1/5
08:33 am
otlk
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Chardan Capital from $3.00 to $1.00. They now have a "neutral" rating on the stock.
High
Report
Oncobiologics (NASDAQ:OTLK) had its price target lowered by analysts at Chardan Capital from $3.00 to $1.00. They now have a "neutral" rating on the stock.
1/3
01:08 am
otlk
Oncobiologics (NASDAQ:OTLK) was downgraded by analysts at
Wall Street Ze
High
Report
Oncobiologics (NASDAQ:OTLK) was downgraded by analysts at
Wall Street Ze
12/28
08:12 pm
otlk
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]
Medium
Report
Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]
12/26
07:07 pm
otlk
Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
Medium
Report
Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]
12/26
05:00 pm
otlk
Outlook Therapeutics Announces New Employment Inducement Grants
Medium
Report
Outlook Therapeutics Announces New Employment Inducement Grants
12/22
08:02 am
otlk
Oncobiologics (NASDAQ:OTLK) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a "buy" rating on the stock.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a "buy" rating on the stock.
12/19
08:35 am
otlk
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 [Yahoo! Finance]
Medium
Report
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 [Yahoo! Finance]
12/19
08:05 am
otlk
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Medium
Report
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
12/10
04:10 am
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Neutral
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/3
04:32 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/24
09:05 am
otlk
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
11/21
02:04 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/13
08:30 am
otlk
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
Medium
Report
Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
11/3
08:35 am
otlk
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
Neutral
Report
Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010
10/31
01:04 pm
otlk
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Oncobiologics (NASDAQ:OTLK) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.